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Inflammation of forebrain and hindbrain nuclei controlling the sympathetic nervous system (SNS) outflow from the
brain to the periphery represents an emerging concept of the pathogenesis of neurogenic hypertension. Angiotensin
II (Ang-II) and prorenin were shown to increase production of reactive oxygen species and pro-inflammatory cytokines
(interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α)) while simultaneously decreasing
production of interleukin-10 (IL-10) in the paraventricular nucleus of the hypothalamus and the rostral ventral lateral
medulla. Peripheral chronic inflammation and Ang-II activity seem to share a common central mechanism contributing
to an increase in sympathetic neurogenic vasomotor tone and entailing neurogenic hypertension. Both hypertension
and obesity facilitate the penetration of peripheral immune cells in the brain parenchyma. We suggest that
renin-angiotensin-driven hypertension encompasses feedback and feedforward mechanisms in the development of
neurogenic hypertension while low-intensity, chronic peripheral inflammation of any origin may serve as a model of a
feedforward mechanism in this condition.
Keywords: Brain inflammation, Neurogenic hypertension, Angiotensin II, Prorenin, Reactive oxygen species, Chronic
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Hypertension is an epidemic health challenge, a proven
major risk factor of the development of cardiovascular
disease and the leading cause of morbidity and mortality
worldwide [1]. Despite the availability of several classes
of antihypertensive drugs, the treatment of hypertension
often remains suboptimal. In addition, the prevalence of
uncontrolled hypertension continues to rise globally [2].
It is well established that inflammation is involved in
the pathogenesis of hypertension [3]. In animals with ex-
perimental hypertension, T cells and macrophages accu-
mulate in the kidneys and peripheral vasculature and
most likely contribute to the end organ damage associ-
ated with this disease [4]. Mice lacking lymphocytes
(Rag1-/- mice) develop blunted hypertension and are pro-
tected from vascular dysfunction and vascular oxidative
stress in response to various stimuli, including angiotensin
II (Ang-II), norepinephrine (NE) and deoxycorticosterone
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unless otherwise stated.transfer of T cells, but not B cells, restores hypertension in
these animals [5]. Dentritic cells from hypertensive mice
exhibit increased expression of the B7 ligands CD80 and
CD86 indicating dendritic cell maturation and activation.
The blocking of these co-stimulatory molecules prevents
hypertension and T cell activation during both Ang-II-
and DOCA-salt-induced hypertension [6].
It is generally accepted that uncontrolled, resistant
hypertension is primarily of neurogenic origin - driven by
chronic hyperactivity of the sympathetic nervous system
(SNS) [7-9]. Clearly, the SNS stimulation of the heart, vas-
culature and kidneys increases blood pressure (BP) by aug-
menting cardiac output, vascular resistance and fluid
retention [8]. However, the SNS also acts as an integrative
interface between the brain and the immune system
[10-12]. Primary (bone marrow and thymus) and second-
ary (spleen and lymph nodes) lymphoid organs are abun-
dantly innervated by autonomic, mostly sympathetic
efferent fibres. NE, the SNS primary neurotransmitter, is
released into the lymphoid tissue and modulates the func-
tion of immune cells. Most of them express receptors for
glucocorticoids, the end product of the hypothalamictral. This is an Open Access article distributed under the terms of the Creative
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pituitary adrenal axis can regulate the magnitude of
innate and adaptive immune responses in multiple ways
[12-14]. Additionally, adipose tissue is directly inner-
vated by the SNS and this innervation plays an import-
ant role in metabolic and endocrine function [15].
Interestingly, perivascular adipose tissue components can
release NE independently from the SNS, possibly exerting
co-stimulatory local control of arterial function [16].
The SNS efferent transmission from the brain to the
peripheral tissues is controlled by several forebrain and
hindbrain nuclei. Particularly important are the paraven-
tricular nucleus of the hypothalamus (PVN), the circum-
ventricular organs (CVOs), the rostral ventral lateral
medulla (RVLM), the anteroventral third ventricle (AV3V)
and the nucleus of the solitary tract (NTS) [17,18]. All of
these structures demonstrate high expression of Ang-II
type 1 receptors (AT1R) [19]. In mammals, CVOs include
the median eminence and adjacent neurohypophysis, the
organum vasculosum lamina terminalis (OVLT), the sub-
fornical organ (SFO) and the area postrema (AP). CVOs
are characterized by their small size, high permeability and
fenestrated capillaries, which enable polypeptide hypothal-
amic hormones to leave the brain without disrupting the
blood-brain barrier (BBB) and permit substances that do
not cross the BBB to trigger changes in the brain function
(that is Ang-II or cytokines) [20].
Pro-inflammatory cytokines produced in the periphery
can feed back to the brain, passing through the BBB at
points of increased permeability in CVOs and/or disrupted
BBB. PVN stimulation with tumor necrosis factor-alpha
(TNF-α) and interleukin-1 beta (IL-1β) results in aug-
mented adrenocorticotropic hormone release, increased
sympathetic outflow and enhanced cardiac sympathetic
afferent reflex with subsequent BP elevation [21-23]. How-
ever, pro-inflammatory cytokines are also produced by glia
and neurons and the recently identified brain inflammatory
response to peripheral inflammation may further contribute
to the development of hypertension [11,24-26]. Interest-
ingly, circulating Ang-II can signal NTS neuronal networks
across the BBB [27] and contributes to BBB disruption
[28-30], enabling its own access to brain areas that are nor-
mally protected by the BBB, including the PVN, RVLM,
and NTS [31]. Also, pro-inflammatory cytokines (IL-1β,
interleukin-6 (IL-6) and TNF-α) may cause dysregulation of
adherens and tight junctions leading to BBB permeabilisa-
tion [32,33]. Therefore, the question of whether the feed-
back or feedforward mechanism prevails and consequently
whether neuroinflammation is a cause or rather the effect
of hypertension remains open.
Renin-Ang-II system and neuroinflammation
Ang-II acting via its AT1R within the PVN is a major
contributor to chronic sympathoexcitation [34]. A slow-pressor Ang-II model of hypertension has been validated
in mice and rats, and it mimics the essential hypertension
in humans as reviewed by Reckelhoff and Romero [35].
Anti-inflammatory cytokine interleukin-10 (IL-10) or min-
ocycline, a tetracycline antibiotic, inhibits the activation of
microglia and reduces BP in this model [36]. Furthermore,
minocycline treatment eradicates the Ang-II-induced in-
crease in mRNAs for pro-inflammatory cytokines (IL-1β;
IL-6; TNF-α) and the decrease in IL-10 mRNA [36-38].
Ang-II-induced hypertension is dependent upon the acti-
vation of the inflammatory nuclear factor kappa B (NFkB)
in the PVN [39], and direct injection of IL-1β into the
PVN or via the intracerebroventricular (ICV) route in-
creases mean BP [23,38,39]. Interestingly, low-intensity
exercise normalizes nicotinamide adenine dinucleotide
phosphate-oxidase (NADPH oxidase) and reactive oxygen
species (ROS) content, suppresses TNF-α and IL-6 mRNA
expression within the PVN and improves baroreflex con-
trol of the heart rate, decreases BP and reduces the low-
frequency component of BP variability [40].
Protracted infusion of Ang-II using osmotic mini-
pumps in mice at the rate of 400 ng/kg/min is a slow-
pressor dose which raises the systolic BP by 20 to 40
mm Hg [28]. In such a model, a significant increase in
leukocyte adhesion on brain venules is observed on day
4 and this effect is maintained on day 14 of Ang-II infu-
sion. Additionally, since the day 14, the leucocyte adhe-
sion is further accompanied by a significant increase in
leukocyte rolling [41]. Importantly, BP increases on day
6 in this model [41], while oxidative stress peaks on day
4 [42] of Ang-II infusion. Therefore, it is likely that the
increased leukocyte adhesion precedes the onset of
hypertension but coincides with the development of oxi-
dative stress. Furthermore, increased leukocyte adhesion
in Ang-II-infused mice is associated with increased BBB
permeability while the reversal of cerebrovascular in-
flammation (leukocyte rolling and adhesion) through
tempol (superoxide dismutase mimetic) treatment is also
associated with restoration of the BBB function [28]. It
was observed that Ang-II affects BBB permeability in the
tissue culture environment [29,30]. Importantly, the in-
creased BBB permeability facilitates leakage of circulat-
ing Ang-II into PVN, NTS and RVLM [31].
In addition to the Ang-II/AT1R mechanism, it has been
proven that another member of the renin-angiotensin sys-
tem (RAS), prorenin, and the prorenin receptor (PRR) plays
a role in the central control of neurogenic hypertension
[43]. Prorenin, like Ang-II, increases pro-inflammatory
cytokine expression (TNF-α and IL-1β) in the NTS via the
NFkB complex [39,44]. Furthermore, prorenin can elicit a
stronger response in cytokine production in Ang-II-
pretreated microglia than in non-pretreated microglia.
Prorenin-induced increases in cytokine expression are erad-
icated by the microglial activation inhibitor minocycline
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attenuates BP development in spontaneously hypertensive
rats (SHR) [46], another animal model of human hyperten-
sion [47,48]. PRR levels are higher in the PVN of human
renin-angiotensinogen double transgenic hypertensive
mice. Knockdown of PRR in the brains of these animals
significantly decreases BP and sympathetic vasomotor tone
[49]. Neuron-specific knockdown of PRR also can reduce
Ang-II formation and BP in the DOCA-salt mouse model
of hypertension [50,51]. Down-regulation of PRR mediated
by viral transfection in the supraoptic nucleus decreases BP
and the expression of inflammatory mediators [46].
The inflammatory mechanisms associated with neuro-
genic hypertension are not restricted to the PVN in the
brain as studies indicate that the NTS exhibits an inflam-
matory state in SHR [52]. The theory of vascular inflam-
mation of the brainstem has been presented elsewhere
[52] and is not discussed in the current review.
SNS activity and hypertensive responses are associated
with the levels of cytokines and oxidative stress markers in
the RVLM. Chronic inhibition of the angiotensin-
converting enzyme in the PVN attenuates both sym-
pathoexcitation and ROS and modulates expression of
cytokines (decreasing TNF-α, IL-1β, IL-6 and MCP-1
while increasing IL-10) in the RVLM in renovascular
hypertension [51]. This effect is due to the high number of
PVN neurons projecting to the RVLM (PVN-RVLM neu-
rons).The number of PVN-RVLM neurons is as much as
seven times the number of PVN neurons projecting to the
spinal cord [53,54], and the PVN-RVLM pathway contrib-
utes to the change in SNS activity observed after activation
of the PVN. Interestingly, the infusion of tempol (super-
oxide dismutase mimetic) in the PVN not only reduces
the ROS response but also decreases BP and SNS activity
in hypertension [55].
In conclusion, Ang-II and prorenin increase the produc-
tion of ROS and mRNAs for pro-inflammatory cytokines
(IL-1β, IL-6, TNF-α), whereas they decrease expression of
IL-10 mRNA in the PVN and RVLM [36-38]. Both prore-
nin and Ang-II act via the NFkB complex [39,44]. Ang-II
also augments BBB permeability in the tissue culture
environment and Ang-II-induced hypertension [28-30].
Inflammatory response and ROS formation in the PVN
and RVLM results in elevated SNS activity and hyperten-
sion. It seems that RAS-induced hypertension represents
a combination of feedforward (direct Ang-II and prorenin
effects on the PVN and RVLM) and feedback (systemic
Ang-II and cytokines signalling via CVOs) mechanisms
that may ultimately promote the development of the
neurogenic form of hypertension.
Lipopolysaccharide-induced neuroinflammation
Lipopolysaccharide (LPS), both in microglial culture and
after ICV injection, elicits an inflammatory response viaToll-like receptor 4 [56,57]. An early and essential step
in this process is the NADPH oxidase-dependent pro-
duction of ROS, which in turn stimulates mitogen-
activated protein kinase (MAPK) pathways. While LPS
activates all three of the major MAPK pathways, the p38
MAPK pathway seems to be most closely associated with
LPS-induced up-regulation of inflammatory mediators
[58], including TNF-α, IL-1β and cyclooxygenase 2
(COX-2), the inducible form of cyclooxygenase regulat-
ing synthesis of prostaglandin E2 (PGE2) [56,57,59,60].
COX-2 and PGE2 are known to activate the SNS
[21,22,61]. ICV LPS also stimulates the hypothalamic
expression of AT1R mRNA, but not the angiotensin-
converting enzyme mRNA, via an NADPH oxidase-
dependent pathway that does not require p38 MAPK [60].
Therefore, Zhang et al.’s [60] study suggests that Ang-II
and the pro-inflammatory cytokines may share a common
mechanism for up-regulation of the AT1R. Ang-II acti-
vates NADPH oxidase-dependent superoxide production
[62] and MAPK signalling pathways [63-66]. NADPH
oxidase-dependent superoxide production up-regulates
AT1R, which contributes to the increased sympathetic
drive [67]. NADPH oxidase-dependent superoxide gener-
ation can be reduced either by blocking NADPH oxidase
activity [62] or by destroying ROS [62,68]. The down-
stream effects of Ang-II- and LPS ROS-generating systems
seem to be differentially regulated as the p38 inhibitor has
no effect on LPS-induced AT1R activity but substantially
reduces mRNA for TNF-α and COX-2 [60].
Intraperitoneal LPS infusion is a well-characterized
rodent model of systemic inflammation. In contrast to
high-dose endotoxin triggering a robust yet transient
inflammatory response, low-dose endotoxin causes low-
grade persistent inflammatory reactions from the host.
This reaction is comparable to low-grade systemic inflam-
mation elicited by periodontal bacteria or a hyperlipidic
diet [69-72]. LPS-induced chronic systemic inflammation
augments levels of TNF-α, IL-1β, IL-6 and inducible nitric
oxide synthase (iNOS) in the RVLM. The expression of
pro-inflammatory factors in this study [25] was compar-
able to that found in the brain of other animal models of
hypertension with neurogenic components, including
chronic infusion of Ang-II and SHR [24,73]. Oxidative
stress resulting from inflammation in the RVLM is down-
stream to microglial activation via a COX-2-dependent
mechanism. COX-2 augments expression of the pro-
inflammatory cytokines and iNOS in the RVLM. The
increase of protein expression and enzyme activity of
COX-2 is reversible by inhibiting microglial activation.
Interestingly, COX-2 activation seems to be downstream
to the loss of endothelial integrity in the RVLM [25].
Microglial activation and the presence of COX-2 and cyto-
kines ameliorate redox-sensitive expression of the Kv4.3
channel protein [25]. Kv4.3 contributes to the transient
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ishes neuronal excitability by increasing the duration of
action potential [74]. By reducing Kv4.3 channel protein
expression, neuroinflammation in the RVLM promotes
hypertension via SNS activation that may result from a
redox-sensitive increase in neuronal excitability. It is
unlikely that the observed neuroinflammation in the
RVLM resulted from direct entry of blood-borne in-
flammatory cytokines as the LPS-promoted long-term
pressor response and the reduction in expression of the
voltage-gated potassium channel Kv4.3 in the RVLM
were antagonized by minocycline (an inhibitor of
microglial activation), the COX-2 inhibitor, pentoxifyl-
line (a cytokine synthesis inhibitor) or tempol (super-
oxide dismutase mimetic), either infused into the
cisterna magna or microinjected bilaterally into the
RVLM. The same treatments were ineffective against
LPS-induced systemic inflammation [25].
To summarize, LPS in microglial culture or provided
either centrally via ICV injection or peripherally via intra-
peritoneal infusion causes endothelial dysfunction and ac-
tivates microglia in the brain nuclei controlling SNS
efferent transmission to induce COX-2-dependent neuro-
inflammation and a subsequent increase in ROS produc-
tion. LPS and Ang-II seem to share a common
mechanism contributing to an increase in sympathetic
neurogenic vasomotor tone and neurogenic hypertensionFigure 1 Feedforward mechanism induced by peripheral chronic inflamma[25,56,57,59,60]. Therefore, peripheral chronic inflamma-
tion may potentially lead to neurogenic hypertension with-
out a pre-existing hypertensive condition, suggesting a
feedforward brain-originated mechanism of peripheral
cardiovascular pressor responses.
Obesity-induced neuroinflammation
Obesity is proven to be a mild inflammatory condition
often accompanied by increased RAS activity [26,75]. A
high-fat diet (HFD) and obesity are associated with the
activation of microglia [76,77] and astrocytes [76,78,79],
suggesting an inflammatory state in the CNS. In rodents,
HFD feeding also initiates an inflammatory cascade in
both the PVN and the SFO, two brain regions that are
critical for the regulation of BP and energy balance. An
increased number of glial cells are Ang-II dependent,
and they are localized specifically within the parvocellu-
lar portion of the PVN and the SFO [80]. Diet-induced
obesity and leptin increase AT1aR expression in the SFO
[80,81]. The silencing of AT1aR in mice or the pharma-
cological blocking of brain AT1R in rats attenuates
leptin-induced SNS activity in renal and brown adipose
tissue, while not attenuating leptin-induced decreases in
food intake or body weight. ICV administration of capto-
pril reverses the effects of leptin on renal and brown adi-
pose tissue SNS activity in rats, suggesting that the
production of Ang-II within the brain contributes to thetion leading to the development of neurogenic hypertension.
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is a mounting evidence for a distributed brain network of
leptin action, encompassing the NTS [82-84], the SFO
[85,86] and the ventromedial and dorsomedial hypothal-
amic nuclei [87], all of which are involved in neurohu-
moral control of the circulation and Ang-II action.
In the normal condition, microglia exist primarily in a
resting state with low levels of CD45 expression, which
increases to high levels upon activation by inflammatory
stimuli such as LPS and in various neurologic conditions
such as Alzheimer’s disease [88-90]. For this reason, it is
not possible to differentiate activated microglia and bone
marrow-derived cells in the CNS only on the basis of
CD45 expression. Such differentiation is feasible using
the radiation bone marrow chimaera model [91]. Using
this model, Buckman et al. showed that less than 10% of
the CD11b+CD45hi cells were of microglial origin; 93%
of the bone marrow-derived cells in the CNS were found
in the parenchyma but were not associated with vessels
and had a distinct stellate morphology characterized by
enlarged somata [92]. The hypothesis that bone marrow-
derived monocytes act like macrophages in the CNS was
supported by Simard et al. [93], who demonstrated that
bone marrow-derived monocytes/macrophages enter the
CNS and phagocytose and degrade amyloid more
effectively than resident microglia in a mouse model of
Alzheimer’s disease. The physiological significance of
immune cell recruitment to the CNS during obesity
and whether these cells are recruited as a consequence
of obesity-induced neuroinflammation and/or contribute
to the neuropathology associated with obesity have yet to
be determined. It is not known if forebrain and hindbrain
nuclei controlling the SNS outflow from the brain to the
peripheral tissues are affected by bone marrow-derived
monocytes. Importantly, the number of CNS-infiltrating
monocytes is positively correlated with body weight, fat
mass and markers of inflammation in adipose tissue
(CD68 and CCL2 gene expression) [92].
In conclusion, obesity initiates an inflammatory cascade
in both the PVN and the SFO. The increase in the number
of glial cells is Ang-II dependent [80].The inflammatory
ability of resident microglial cells might potentially be
enhanced by HFD-induced recruitment of bone marrow-
derived monocytes to the brain [92]. Therefore, obesity
primarily not associated with hypertension may trigger
feedforward launching of neurogenic hypertension by a
brain-originated mechanism.
Future directions
Inflammation of forebrain and hindbrain nuclei control-
ling the SNS efferent transmission from the brain to the
periphery seems to constitute a key element in the devel-
opment of neurogenic hypertension. Marvar et al. [49]
proposed for the first time a feedforward mechanism witha central role of Ang-II in brain inflammatory response and
subsequent SNS activation. We suggest that RAS-driven
hypertension encompasses feedback and feedforward
mechanisms, while chronic low-intensity peripheral inflam-
mation of any origin may serve as an example of a feed-
forward mechanism in the development of neurogenic
hypertension (Figure 1). Chronic systemic inflammation
and Ang-II (or even prorenin) may share the same signal-
ling pathways, ultimately leading to increased production of
pro-inflammatory cytokines in brain nuclei controlling car-
diovascular function.
Clearly, the results from animal studies discussed
above open up enormous potential for translation, both
in terms of pharmacological therapy and lifestyle modifi-
cations. Sartans (AT1R blockers) are already commonly
used for therapy in hypertension, diabetes and stroke but
have not been studied in humans in the context of their
central anti-inflammatory action. Nevertheless, the safety
profile of this group of drugs is relatively well known. An-
tibiotics, ROS scavengers and immunosuppressive agents
are also likely candidates for controlled randomized trials
in humans. Finally, low-intensity but repetitive exercise
and a low-fat diet represent a safe approach to reducing
the risk of brain inflammation and the subsequent devel-
opment of neurogenic hypertension.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PJW drafted and wrote the manuscript. MR, MWW and UD commented and
revised the manuscript. All authors have read and approved the final version
of the manuscript.
Acknowledgements
The study received funding from the Warsaw Medical University Grant No.
1M24/N/2015.
Author details
1Institute of Human Physiology, Medical University of Gdansk, Tuwima Str. 15,
80-210 Gdansk, Poland. 2Department of Immunopathology of Infectious and
Parasitic Diseases, Medical University of Warsaw, Pawinskiego Str. 3c, 02-106
Warsaw, Poland. 3Department of Laboratory Diagnostics and Clinical
Immunology of Developmental Age, Medical University of Warsaw,
Marszalkowska Str. 24, 00-576 Warsaw, Poland.
Received: 27 February 2015 Accepted: 23 April 2015
References
1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global
burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.
2. Chobanian AV. Shattuck Lecture. The hypertension paradox–more
uncontrolled disease despite improved therapy. N Engl J Med.
2009;361:878–87.
3. Coffman TM. Under pressure: the search for the essential mechanisms of
hypertension. Nat Med. 2011;17:1402–9.
4. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, et al.
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in
angiotensin II-induced end-organ damage. Hypertension. 2000;36:282–90.
5. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role
of the T cell in the genesis of angiotensin II induced hypertension and
vascular dysfunction. J Exp Med. 2007;204:2449–60.
Winklewski et al. Journal of Neuroinflammation  (2015) 12:85 Page 6 of 76. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, et al. Inhibition
and genetic ablation of the B7/CD28 T-cell costimulation axis prevents
experimental hypertension. Circulation. 2010;122:2529–37.
7. Dampney RA, Horiuchi J, Killinger S, Sheriff MJ, Tan PS, McDowall LM. Long-
term regulation of arterial blood pressure by hypothalamic nuclei: some
critical questions. Clin Exp Pharmacol Physiol. 2005;32:419–25.
8. Esler M. The sympathetic nervous system through the ages: from Thomas
Willis to resistant hypertension. Exp Physiol. 2011;96:611–22.
9. Takahashi H. Upregulation of the renin-angiotensin-aldosterone-ouabain
system in the brain is the core mechanism in the genesis of all types of
hypertension. Int J Hypertens. 2012;2012:242786.
10. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve–an
integrative interface between two supersystems: the brain and the immune
system. Pharmacol Rev. 2000;52:595–638.
11. Paton JF, Waki H. Is neurogenic hypertension related to vascular
inflammation of the brainstem? Neurosci Biobehav Rev. 2009;33:89–94.
12. Winklewski PJ, Radkowski M, Demkow U. Cross-talk between the inflammatory
response, sympathetic activation and pulmonary infection in the ischemic
stroke. J Neuroinflammation. 2014;11:213.
13. Bellinger DL, Millar BA, Perez S, Carter J, Wood C, ThyagaRajan S, et al.
Sympathetic modulation of immunity: relevance to disease. Cell Immunol.
2008;252:27–56.
14. Nance DM, Sanders VM. Autonomic innervation and regulation of the
immune system (1987-2007). Brain Behav Immun. 2007;21:736–45.
15. Fliers E, Kreier F, Voshol PJ, Havekes LM, Sauerwein HP, Kalsbeek A, et al.
White adipose tissue: getting nervous. J Neuroendocrinol. 2003;15:1005–10.
16. Ayala-Lopez N, Martini M, Jackson WF, Darios E, Burnett R, Seitz B, et al.
Perivascular adipose tissue contains functional catecholamines.
Pharmacol Res Perspect. 2014;2:e00041.
17. Kasparov S, Teschemacher AG. Altered central catecholaminergic
transmission and cardiovascular disease. Exp Physiol. 2008;93:725–40.
18. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain
and cardiovascular diseases: common neurogenic background of
cardiovascular, metabolic and inflammatory diseases. J Physiol Pharmacol.
2010;61:509–21.
19. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al.
The brain renin-angiotensin system: location and physiological roles. Int J
Biochem Cell Biol. 2003;35:901–18.
20. Ganong WF. Circumventricular organs: definition and role in the regulation
of endocrine and autonomic function. Clin Exp Pharmacol Physiol.
2000;27:422–7.
21. Felder RB, Yu Y, Zhang ZH, Wei SG. Pharmacological treatment for heart
failure: a view from the brain. Clin Pharmacol Ther. 2009;86:216–20.
22. Felder RB. Mineralocorticoid receptors, inflammation and sympathetic drive
in a rat model of systolic heart failure. Exp Physiol. 2010;95:19–25.
23. Shi Z, Gan XB, Fan ZD, Zhang F, Zhou YB, Gao XY, et al. Inflammatory
cytokines in paraventricular nucleus modulate sympathetic activity and
cardiac sympathetic afferent reflex in rats. Acta Physiol. 2011;203:289–97.
24. Saavedra JM, Angiotensin II. AT(1) receptor blockers as treatments for
inflammatory brain disorders. Clin Sci. 2012;123:567–90.
25. Wu KL, Chan SH, Chan JY. Neuroinflammation and oxidative stress in rostral
ventrolateral medulla contribute to neurogenic hypertension induced by
systemic inflammation. J Neuroinflammation. 2012;9:212.
26. de Kloet AD, Krause EG, Shi PD, Zubcevic J, Raizada MK, Sumners C.
Neuroimmune communication in hypertension and obesity: a new
therapeutic angle? Pharmacol Ther. 2013;138:428–40.
27. Paton JF, Wang S, Polson JW, Kasparov S. Signalling across the blood brain
barrier by angiotensin II: novel implications for neurogenic hypertension.
J Mol Med. 2008;86:705–10.
28. Zhang M, Mao Y, Ramirez SH, Tuma RF, Chabrashvili T. Angiotensin II
induced cerebral microvascular inflammation and increased blood-brain
barrier permeability via oxidative stress. Neuroscience. 2010;171:852–8.
29. Guillot FL, Audus KL. Angiotensin peptide regulation of bovine brain
microvessel endothelial cell monolayer permeability. J Cardiovasc
Pharmacol. 1991;18:212–8.
30. Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB
permeability via activation of the AT(1) receptor in brain endothelial cells.
J Cereb Blood Flow Metab. 2009;29:640–7.
31. Biancardi VC, Son SJ, Ahmadi S, Filosa JA, Stern JE. Circulating angiotensin II
gains access to the hypothalamus and brain stem during hypertension via
breakdown of the blood-brain barrier. Hypertension. 2014;63:572–9.32. Labus J, Häckel S, Lucka L, Danker K. Interleukin-1β induces an inflammatory
response and the breakdown of the endothelial cell layer in an improved
human THBMEC-based in vitro blood-brain barrier model. J Neurosci
Methods. 2014;228:35–45.
33. Rochfort KD, Collins LE, Murphy RP, Cummins PM. Downregulation of
blood-brain barrier phenotype by proinflammatory cytokines involves
NADPH oxidase-dependent ROS generation: consequences for interendothelial
adherens and tight junctions. PLoS One. 2014;9:e101815.
34. Paton JF, Raizada MK. Neurogenic hypertension. Exp Physiol. 2010;95:569–71.
35. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced
hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893–912.
36. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, et al. Brain microglial
cytokines in neurogenic hypertension. Hypertension. 2010;56:297–303.
37. Kang YM, Ma Y, Zheng JP, Elks C, Sriramula S, Yang ZM, et al. Brain nuclear
factor-kappa B activation contributes to neurohumoral excitation in
angiotensin II-induced hypertension. Cardiovasc Res. 2009;82:503–12. 2009a.
38. Kang YM, He RL, Yang LM, Qin DN, Guggilam A, Elks C, et al. Brain tumour
necrosis factor-alpha modulates neurotransmitters in hypothalamic
paraventricular nucleus in heart failure. Cardiovasc Res. 2009;83:737–46.
39. Cardinale JP, Sriramula S, Mariappan N, Agarwal D, Francis J. Angiotensin
II-induced hypertension is modulated by nuclear factor-kappa B in the
paraventricular nucleus. Hypertension. 2012;59:113–21.
40. Masson GS, Costa TS, Yshii L, Fernandes DC, Soares PP, Laurindo FR, et al.
Time-dependent effects of training on cardiovascular control in spontaneously
hypertensive rats: role for brain oxidative stress and inflammation and
baroreflex sensitivity. PLoS One. 2014;9:e94927.
41. Welch WJ, Chabrashvili T, Solis G, Chen Y, Gill PS, Aslam S, et al. Role of
extracellular superoxide dismutase in the mouse angiotensin slow pressor
response. Hypertension. 2006;48:934–41.
42. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling
KK, et al. RNA silencing in vivo reveals role of p22phox in rat angiotensin
slow pressor response. Hypertension. 2006;47:238–44.
43. Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc
Nephrol. 2010;21:18–23.
44. Zubcevic J, Jun JY, Lamont G, Murca TM, Shi P, Yuan W, et al. Nucleus of
the solitary tract(pro)renin receptor-mediated antihypertensive effect
involves nuclear factor kappa B-cytokine signaling in the spontaneously
hypertensive rat. Hypertension. 2013;61:622–7.
45. Shi P, Grobe JL, Desland FA, Zhou G, Shen XZ, Shan Z, et al. Direct
pro-inflammatory effects of prorenin on microglia. PLoS One. 2014;9:e92937.
46. Shan Z, Shi P, Cuadra AE, Dong Y, Lamont GJ, Li Q, et al. Involvement of the
brain(pro)renin receptor in cardiovascular homeostasis. Circ Res. 2010;107:934–8.
47. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive
rats. Jpn Circ J. 1963;27:282–93.
48. Friese RS, Mahboubi P, Mahapatra NR, Mahata SK, Schork NJ, Schmid-
Schönbein GW, et al. Common genetic mechanisms of blood pressure
elevation in two independent rodent models of human essential
hypertension. Am J Hypertens. 2005;18:633–52.
49. Marvar PJ, Lob H, Vinh A, Zarreen F, Harrison DG. The central nervous system
and inflammation in hypertension. Curr Opin Pharmacol. 2011;11:156–61.
50. Li W, Peng H, Cao T, Sato R, McDaniels SJ, Kobori H, et al. Brain-targeted
(pro)renin receptor knockdown attenuates angiotensin II dependent
hypertension. Hypertension. 2012;59:1188–94.
51. Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, et al. Ang II
potentiates prorenin-induced TNFa production. Hypertension. 2014;63:316–23.
52. Waki H, Gouraud SS, Maeda M, Raizada MK, Paton JF. Contributions of
vascular inflammation in the brainstem for neurogenic hypertension.
Respir Physiol Neurobiol. 2011;178:422–8.
53. Agarwal D, Welsch MA, Keller JN, Francis J. Chronic exercise modulates RAS
components and improves balance between pro- and anti-inflammatory
cytokines in the brain of SHR. Basic Res Cardiol. 2011;106:1069–85.
54. Kumagai H, Oshima N, Matsuura T, Iigaya K, Imai M, Onimaru H, et al.
Importance of rostral ventrolateral medulla neurons in determining efferent
sympathetic nerve activity and blood pressure. Hypertens Res. 2012;35:132–41.
55. Su Q, Qin DN, Wang FX, Ren J, Li HB, Zhang M, et al. Inhibition of reactive
oxygen species in hypothalamic paraventricular nucleus attenuates the
renin-angiotensin system and proinflammatory cytokines in hypertension.
Toxicol Appl Pharmacol. 2014;276:115–20.
56. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, et al. NADPH oxidase
mediates lipopolysaccharide-induced neurotoxicity and proinflammatory
gene expression in activated microglia. J Biol Chem. 2004;279:1415–21.
Winklewski et al. Journal of Neuroinflammation  (2015) 12:85 Page 7 of 757. Qin L, Li G, Qian X, Liu Y, Wu X, Liu B, et al. Interactive role of the toll-like
receptor4 and reactive oxygen species in LPS-induced microglia activation.
Glia. 2005;52:78–84.
58. Krishna M, Narang H. The complexity of mitogen-activated protein kinases
(MAPKs) made simple. Cell Mol Life Sci. 2008;65:3525–44.
59. Pawate S, Shen Q, Fan F, Bhat NR. Redox regulation of glial inflammatory
response to lipopolysaccharide and interferon gamma. J Neurosci Res.
2004;77:540–51.
60. Zhang ZH, Yu Y, Wei SG, Felder RB. Centrally administered
lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-
dependent mitogen-activated protein kinase signaling. J Hypertens.
2010;28:806–16.
61. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal
sympathetic activation by blood-borne TNF-alpha in rat: the role of central
prostaglandins. Am J Physiol Regul Integr Comp Physiol. 2003;284:R916–27.
62. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, et al. Superoxide
mediates sympathoexcitation in heart failure: roles of angiotensin II and
NAD(P)H oxidase. Circ Res. 2004;95:937–44.
63. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY. NADPH oxidase-
derived superoxide anion mediates angiotensin II-induced pressor effect via
activation of p38 mitogen-activated protein kinase in the rostral ventrolateral
medulla. Circ Res. 2005;97:772–80.
64. Zucker IH, Gao L. The regulation of sympathetic nerve activity by
angiotensin II involves reactive oxygen species and MAPK. Circ Res.
2005;97:737–9.
65. Wei SG, Yu Y, Zhang ZH, Weiss RM, Felder RB. Mitogen-activated protein
kinases mediate upregulation of hypothalamic angiotensin II type 1
receptors in heart failure rats. Hypertension. 2008;52:679–86.
66. Wei SG, Yu Y, Zhang ZH, Weiss RM, Felder RB. Angiotensin II-triggered p44/42
mitogen-activated protein kinase mediates sympathetic excitation in heart
failure rats. Hypertension. 2008;52:342–50.
67. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, et al.
Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation
and NAD(P)H oxidase in RVLM. Am J Physiol Heart Circ Physiol.
2005;288:H2271–9.
68. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in
the central nervous system activation and sympathoexcitation of myocardial
infarction-induced heart failure. Circ Res. 2004;94:402–9.
69. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al.
Changes in gut microbiota control metabolic endotoxemia-induced
inflammation in high-fat diet-induced obesity and diabetes in mice.
Diabetes. 2008;57:1470–81.
70. Terra X, Montagut G, Bustos M, Llopiz N, Ardèvol A, Bladé C, et al. Grape-
seed procyanidins prevent low-grade inflammation by modulating cytokine
expression in rats fed a high-fat diet. J Nutr Biochem. 2009;20:210–8.
71. Endo Y, Tomofuji T, Ekuni D, Irie K, Azuma T, Tamaki N, et al. Experimental
periodontitis induces gene expression of proinflammatory cytokines in liver
and white adipose tissue in obesity. J Periodontol. 2010;81:520–6.
72. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides,
and innate immunity in the pathogenesis of obesity and cardiovascular risk.
Endocr Rev. 2010;31:817–44.
73. Marvar PJ, Thabet SR, Buzik TJ, Lob HE, McCann LA, Weyand C, et al. Central
and peripheral mechanisms of T-lymphocyte activation and vascular
inflammation produced by angiotensin II-induced hypertension. Circ Res.
2010;107:263–70.
74. Carrasquillo Y, Burkhalter A, Nerbonne JM. A-type K+ channels encoded by
Kv4.2, Kv4.3 and Kv1.4 differentially regulate intrinsic excitability of cortical
pyramidal neurons. J Physiol. 2012;590:3877–90.
75. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic
inflammation in fat plays a crucial role in the development of obesity-related
insulin resistance. J Clin Invest. 2003;112:1821–30.
76. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al.
Obesity is associated with hypothalamic injury in rodents and humans.
J Clin Invest. 2012;122:153–62.
77. Yi CX, Al-Massadi O, Donelan E, Lehti M, Weber J, Ress C, et al. Exercise
protects against high-fat diet-induced hypothalamic inflammation.
Physiol Behav. 2012;106:485–90.
78. Buckman LB, Thompson MM, Moreno HN, Ellacott KL. Regional astrogliosis
in the mouse hypothalamus in response to obesity. J Comp Neurol.
2013;521:1322–33.79. Hsuchou H, He Y, Kastin AJ, Tu H, Markadakis EN, Rogers RC, et al. Obesity
induces functional astrocytic leptin receptors in hypothalamus. Brain.
2009;132:889–902.
80. de Kloet AD, Pioquinto DJ, Nguyen D, Wang L, Smith JA, Hiller H, et al. Obesity
induces neuroinflammation mediated by altered expression of the renin-
angiotensin system in mouse forebrain nuclei. Physiol Behav. 2014;136:31–8.
81. Hilzendeger AM, Morgan DA, Brooks L, Dellsperger D, Liu X, Grobe JL, et al.
A brain leptin-renin angiotensin system interaction in the regulation of
sympathetic nerve activity. Am J Physiol Heart Circ Physiol. 2012;303:H197–206.
82. Arnold AC, Shaltout HA, Gallagher PE, Diz DI. Leptin impairs cardiovagal
baroreflex function at the level of the solitary tract nucleus. Hypertension.
2009;54:1001–8.
83. Hayes MR, Skibicka KP, Leichner TM, Guarnieri DJ, DiLeone RJ, Bence KK,
et al. Endogenous leptin signaling in the caudal nucleus tractus solitarius
and area postrema is required for energy balance regulation. Cell Metab.
2010;11:77–83.
84. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, Rahmouni K. Leptin
signaling in the nucleus tractus solitarii increases sympathetic nerve activity
to the kidney. Hypertension. 2009;53:375–80.
85. Smith PM, Chambers AP, Price CJ, Ho W, Hopf C, Sharkey KA, et al. The
subfornical organ: a central nervous system site for actions of circulating
leptin. Am J Physiol Regul Integr Comp Physiol. 2009;296:R512–20.
86. Smith PM, Ferguson AV. Cardiovascular actions of leptin in the subfornical organ
are abolished by diet-induced obesity. J Neuroendocrinol. 2012;24:04–510.
87. Marsh AJ, Fontes MA, Killinger S, Pawlak DB, Polson JW, Dampney RA.
Cardiovascular responses evoked by leptin acting on neurons in the
ventromedial and dorsomedial hypothalamus. Hypertension. 2003;42:488–93.
88. Akiyama H, Ikeda K, Katoh M, McGeer EG, McGeer PL. Expression of MRP14,
27E10, interferon-alpha and leukocyte common antigen by reactive microglia
in postmortem human brain tissue. J Neuroimmunol. 1994;50:195–201.
89. Sedgwick JD, Ford AL, Foulcher E, Airriess R. Central nervous system
microglial cell activation and proliferation follows direct interaction with
tissue-infiltrating T cell blasts. J Immunol. 1998;160:5320–30.
90. Nikodemova M, Watters JJ. Efficient isolation of live microglia with preserved
phenotypes from adult mouse brain. J Neuroinflammation. 2012;9:147.
91. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW.
Obesity is associated with macrophage accumulation in adipose tissue.
J Clin Invest. 2003;112:1796–808.
92. Buckman LB, Hasty AH, Flaherty DK, Buckman CT, Thompson MM, Matlock BK,
et al. Obesity induced by a high-fat diet is associated with increased immune
cell entry into the central nervous system. Brain Behav Immun. 2014;35:33–42.
93. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived
microglia play a critical role in restricting senile plaque formation in
Alzheimer’s disease. Neuron. 2006;49:489–502.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
